Successful Control of Myasthenic Crisis with Ravulizumab
Author Information
Author(s): Muacevic Alexander, Adler John R, Uchi Takafumi, Konno Shingo, Kihara Hideo, Sugimoto Hideki
Primary Institution: Toho University Ohashi Medical Center
Hypothesis
Can ravulizumab effectively manage a myasthenic crisis in patients with myasthenia gravis?
Conclusion
Ravulizumab was effective in improving respiratory function and enabling ventilator weaning in a patient with a myasthenic crisis.
Supporting Evidence
- This case is the first report of successful weaning from mechanical ventilation after treatment with ravulizumab in a patient with a myasthenic crisis.
- Ravulizumab improved the patient's respiratory function, allowing for hospital discharge.
- The patient had previously received multiple treatments without success before ravulizumab was introduced.
Takeaway
A 71-year-old woman with a severe muscle weakness condition got better after receiving a new medicine called ravulizumab, which helped her breathe again.
Methodology
This case study involved a 71-year-old woman treated with ravulizumab after experiencing a myasthenic crisis.
Limitations
The findings are based on a single case report, limiting generalizability.
Participant Demographics
71-year-old woman with a history of complicated type 1 diabetes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website